As of Aug 18
| -0.02 / -0.47%|
The 1 analysts offering 12-month price forecasts for Caladrius Biosciences Inc have a median target of 7.00, with a high estimate of 7.00 and a low estimate of 7.00. The median estimate represents a +63.55% increase from the last price of 4.28.
The current consensus among 1 polled investment analysts is to Buy stock in Caladrius Biosciences Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.